Counting chickens before the eggs hatch: Associating new product development portfolios with shareholder expectations in the pharmaceutical sector

International Journal of Research in Marketing

Volumn 25, Issue 4, 2008, Pages 261-272

  Grewal, Rajdeep ^a   Chakravarty, Anindita ^a   Ding, Min ^a   Liechty, John ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Drug development; Marketing and health; New product portfolios; Pharmaceutical industry; Shareholder value

Indexed keywords

EID: 55949097756     PISSN: 01678116     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijresmar.2008.07.001     Document Type: Article

References (78)

1. Arlington S., Barnett S., Hughes S., and Palo J. Pharma 2010: The Threshold of Innovation: IBM Business Consulting Services (2006)
2. Barkema H.G., and Vermeulen F. International expansion through start-up or acquisition: A learning perspective. Academy of Management Journal 41 1 (1998) 7-26
3. Bharadwaj A.S., Bharadwaj S.G., and Konsynski B.R. Information technology effects on firm performance as measured by Tobin's q. Management Science 45 7 (1999) 1008-1024
4. Bijmolt T.H.A., Paas L.J., and Vermunt J.K. Country and consumer segmentation: Multi-level latent class analysis of financial product ownership. International Journal of Research in Marketing 21 4 (2004) 324-340
5. Black F. The magic in earnings: Economic earnings versus financial earnings. Financial Analysts Journal 36 6 (1980) 19-24
6. Bordley R. Determining the appropriate depth and breadth of a firm's product portfolio. Journal of Marketing Research 40 1 (2003) 39-53
7. Bower D.J. New product development in the pharmaceutical industry: Pooling network resources. Journal of Product Innovation Management 10 5 (1993) 367-375
8. Bowman E.H., and Hurry D. strategic through the option lens: An integrated view of resource investments and the incremental-choice process. Academy of Management Review 18 (1993) 760-782 (October)
9. Bozdogan H. Model selection and the Akaike's Information Criterion (AIC): The general theory and its analytical extensions. Psychometrika 52 3 (1987) 345-370
10. Brealey R.A., and Myers S.C. Principles of corporate finance (2003), McGraw-Hill, New York
11. Carbonell P., and Rodriguez A.I. The impact of market characteristics and innovation speed on perceptions of positional advantage and new product performance. International Journal of Research in Marketing 23 1 (2006) 1-12
12. Cardinal L. Technological innovation in the pharmaceutical industry: The use of organizational control in managing research and development. Organization Science 12 1 (2001) 19-36
13. Cardinal L., and Hatfield D.E. The location of corporate research and innovative productivity in the U.S. pharmaceutical industry. International Journal of Healthcare Technology and Management 2 5/6 (2000) 576-590
14. Cardinal L., and Hatfield D.E. Internal knowledge generation: The corporate research laboratory and innovative productivity in the pharmaceutical industry. Journal of Engineering and Technology Management 17 (2000) 247-271
15. Chandy R., Hopstaken B., Narasimhan O., and Prabhu J. From invention to innovation: Conversion ability in product development. Journal of Marketing Research 43 3 (2006) 494-508
16. Christophe S.E., and Lee H. What matters about internationalization: A market-based assessment. Journal of Business Research 58 5 (2005) 636-643
17. Chung K.H., and Pruitt S.W. A simple approximation of Tobin's q. Financial Management 23 3 (1994) 70-74
18. Cooper R., Edgett S., and Kleinschmidt E. Portfolio management for new products (1998), Perseus Books, Reading, MA
19. Cooper R., Edgett S., and Kleinschmidt E. Portfolio management for new product development: Results of an industry practices study. Research Technology Management 31 4 (2001) 361-380
20. Cooper R., Edgett S., and Kleinschmidt E. Benchmarking best NPD practices-II. Research Technology Management 47 3 (2004) 50-59
21. Danzon P.M., Nicholson S., and Pereira N.S. Productivity in pharmaceutical-biotechnology R&D: The role of experience and alliances. Journal of Health Economics 24 2 (2005) 317-339
22. Dayton C.M., and MacReady G.B. Concomitant variable latent-class models. Journal of the American Statistical Association 83 401 (1988) 173-178
23. DeSarbo W.S., and Cron W.L. A maximum likelihood methodology for clusterwise linear regression. Journal of Classification 5 2 (1988) 249-282
24. Desiraju R., Nair H., and Chintagunta P. Diffusion of new pharmaceutical drugs in developing and developed nations. International Journal of Research in Marketing 21 4 (2004) 341-357
25. DiMasi J.A., Hansen R.W., Grabowski H.G., and Lasagna L. Research and development costs for new drugs by therapeutic category: A study of the U.S. Pharmaceutical industry. PharmacoEconomics 7 2 (1995) 152-169
26. DiMasi J.A., Hansen R.W., and Grabowski H.G. The price of innovation: New estimates of drug development costs. Journal of Health Economics 22 2 (2003) 151-185
27. Ding M., and Eliashberg J. Structuring the new product development pipeline. Management Science 48 3 (2002) 343-363
28. Dutta S., Narasimhan O., and Rajiv S. Success in high-technology markets: Is marketing capability critical?. Marketing Science 18 4 (1999) 547-568
29. Evans S.J. strategic flexibility for high technology maneuvers: A conceptual framework. Journal of Management Studies 28 1 (1991) 69-89
30. Everitt B.S., and Hand D.J. Finite mixture distributions (1981), Chapman and Hall, London
31. Fama E.F., Fisher L., Jensen M.C., and Roll R. The adjustment of stock price to new information. International Economic Review 10 1 (1969) 1-21
32. Goldenberg J., Libai B., Moldovan S., and Muller E. The NPV of bad news. International Journal of Research in Marketing 24 3 (2007) 186-200
33. Grabowski H.G., Vernon J., and DiMasi J.A. Returns on research and development for 1990s new drug introductions. PharmacoEconomics 20 3 (2002) 11-29
34. Grewal R., and Tansuhaj P. Building organizational capabilities for managing economic crises: The role of market orientation and strategic flexibility. Journal of Marketing 65 2 (2001) 67-80
35. Grewal R., Lilien G.L., and Mallapragada G. Location, location, location: How network embeddedness affects project success in open source systems. Management Science 52 7 (2006) 1043-1056
36. Griffin A. PDMA research on new product development practices: Updating trends and benchmarking best practices. Journal of Product Innovation Management 14 6 (2007) 429-458
37. Griliches Z. Productivity, R&D, and the data constraint. American Economic Review 84 1 (1984) 1-23
38. Henderson R., and Cockburn I. Measuring competence? Exploring firm effects in pharmaceutical research. Strategic Management Journal 15 (1994) 63-84
39. Hutchinson J.W., Kamakura W.A., and Lynch J.G. Unobserved heterogeneity as an alternative explanation for 'reversal' effects in behavioral research. Journal of Consumer Research 27 (2000) 323-344 (December)
40. Kahya E. Prediction of business failure: A funds flow approach. Managerial Finance 23 3 (1997) 64-71
41. Kalaignanam K., Shankar V., and Varadarajan R.P. Asymmetric new product development alliances: Win-win or win-lose partnerships?. Management Science 53 (2007) 357-374
42. Kamakura W.A., Wedel M., and Agrawal J. Concomitant variable latent class models for conjoint analysis. International Journal of Research in Marketing 11 (1994) 451-464
43. Kerin R.A., and Sethuraman R. Exploring the brand value-shareholder value nexus for consumer goods companies. Journal of the Academy of Marketing Science 26 4 (1998) 260-273
44. Kim C.W., Hwang P., and Burgers W.P. Multinationals' diversification and the risk-return trade-off. Strategic Management Journal 14 4 (1993) 275-286
45. Krishnan V., and Ulrich K.T. Product development decisions: A review of the literature. Management Science 47 1 (2001) 1-21
46. Kumar V., and Peterson J.A. Using a customer-level marketing strategy to enhance firm performance: A review of theoretical and empirical evidence. Journal of the Academy of Marketing Science 33 4 (2005) 504-519
47. Lee R.P., and Grewal R. Strategic responses to new technologies and their impact on firm performance. Journal of Marketing 68 4 (2004) 157-171
48. Leenders M.A.A.M., and Wierenga B. The effect of the marketing-R&D interface on new product performance: The critical role of resources and scope. International Journal of Research in Marketing 25 1 (2008) 56-68
49. Luo Y. Product diversification in international joint ventures: Performance implications in an emerging market. Strategic Management Journal 23 1 (2002) 1-20
50. Mahmoud A., Danzon P.M., Barton J.H., and Mugerwa R.D. Product development priorities. Disease Control Priorities in Developing Countries (2006), Oxford University Press, New York
51. Mizik N., and Jacobson R. Trading off between value creating and value appropriation: The financial implications of shifts in strategic emphasis. Journal of Marketing 67 (2003) 63-76 (January)
52. PDMA. PDMA foundation's comparative performance assessment study: Product development and management foundation, Mount Laurel: NJ (2004)
53. Platt H.D., and Platt M.B. A note on the use of industry-relative ratios in bankruptcy prediction. Journal of Banking and Finance 15 6 (1991) 1183-1194
54. Powell W.W., and Brantley P. Competitive cooperation in commercial biotechnology: Learning through networks?. In: N. R.G., and Eccles Nohria (Eds). Networks and Organizations (1992), Harvard Business School Press, Boston
55. Powell W.W., Koput K.W., and Smith-Doerr L. Interorganizational collaboration and the locus of innovation: Networks of learning in biotechnology. Administrative Science Quarterly 41 1 (1996) 116-145
56. Putsis W.P., and Bayus B.L. An empirical analysis of firms' product line decisions. Journal of Marketing Research 38 1 (2001) 110-118
57. Quelch J.B., and Kenny D. The logic of product-line extensions. Harvard Business Review 72 6 (1994) 60
58. Rust R.T., Ambler T., Carpenter G.S., Kumar V., and Srivastava R.K. Measuring marketing productivity: Current knowledge and future directions. Journal of Marketing 68 4 (2004) 76-89
59. Sanchez R. Strategic flexibility in product competition. Strategic Management Journal 16 (1995) 135-159 (Summer)
60. Sanchez R. Modular architectures in the marketing process. Journal of Marketing 63 (1999) 92-111 (Special Issue)
61. Scherer F.M. The link between gross profitability and pharmaceutical R&D spending. Health Affairs 25 (2001) 116-120
62. Shan W., Walker G., and Kogut B. Interfirm cooperation and startup innovation in the biotechnology industry. Strategic Management Journal 15 5 (1994) 387-394
63. Shankar V. Strategic marketing decision models for the pharmaceutical industry. In: Wiersenga B. (Ed). Handbook for Marketing Decision Models (2007) Springer Science and Business Media, International Series in Operational Research and Management Science
64. Sharma A., and Lacey N. Linking product development outcomes to market valuation of the firm: The case of the U.S. pharmaceutical industry. Journal of Product Innovation Management 21 5 (2004) 297-308
65. Simon C.J., and Sullivan M.W. The measurement and determinants of brand equity: A financial approach. Marketing Science 12 1 (1993) 28-52
66. Slade O. Pharmaceutical portfolio management strategy (2006), Cutting Edge Information, Durham: NC
67. Sorescu A.B., Chandy R.K., and Prabhu J.C. Sources and financial consequences of radical innovations: Insights from pharmaceuticals. Journal of Marketing 67 4 (2003) 82-102
68. Srinivasan R. Dual distribution and intangible firm value: Franchising in restaurant chains. Journal of Marketing 70 3 (2006) 120-135
69. Srivastava R.K., Shervani T.A., and Fahey L. Market-based assets and shareholder value: A framework for analysis. Journal of Marketing 62 1 (1998) 2-18
70. Srivastava R.K., Shervani T.A., and Fahey L. Marketing, business processes, and shareholder value: An organizationally embedded view of marketing activities and the discipline of marketing. Journal of Marketing 63 (1999) 168-179 (Special Issue)
71. Stremersch S., and Tellis G.J. Understanding and managing international growth of new products. International Journal of Research in Marketing 21 4 (2004) 421-438
72. Titterington D.M., Smith A.F.M., and Makov U.E. Statistical Analysis of Finite Mixture Distributions (1985), John Wiley & Sons, Chichester, England
73. Trombetta B. Industry audit. Pharmaceutical Executive (2005) September
74. Vorberg D., and Ulrich R. Random search with unequal search rates: Serial and parallel generalizations of McGill's model. Journal of Mathematical Psychology 31 1 (1987) 1-23
75. Voss G.B., Montoya-Weiss M., and Voss Z.G. Aligning innovation with market characteristics in the nonprofit professional theater industry. Journal of Marketing Research 43 2 (2006) 296-302
76. Wedel M., and Kamakura W.A. Market segmentation: Conceptual and methodological foundations (2000), Kluwer, Boston, MA
77. Wernerfelt B., and Montgomery C.A. Tobin's q and the importance of focus in firm performance. American Economic Review 78 1 (1988) 246-250
78. Wuyts S., Dutta S., and Stremersch S. Portfolios of interfirm agreements in technology-intensive markets: Consequences for innovation and profitability. Journal of Marketing 68 2 (2004) 88-100